KWANGDONG PHARMACEUTICAL CO.,LTD
Financials
Valuation Metrics
KWANGDONG PHARMACEUTICAL CO.,LTD's Market Cap is ₩3073B. At end of 2025 it was ₩2918B. Ranked #597 of 2,436 in KR market (top 25%), #364 of 787 on KOSPI (top 46%), #63 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 27%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 307.26B KRW | KR#597/2,436 Sec#63/234 |
| Revenue | 1.69T KRW | KR#283/2,436 Sec#8/234 |
| Net Income | 22.17B KRW | KR#617/2,436 Sec#41/234 |
| Total Assets | 1.32T KRW | KR#396/2,436 Sec#20/234 |
| Net Assets | 712.31B KRW | KR#371/2,436 Sec#25/234 |
| Employees | 1,072 | KR#242/2,436 Sec#15/234 |
| Value | ||
| P/E | 13.86x | KR#937/2,436 Sec#56/234 |
| P/B | 0.43x | KR#671/2,436 Sec#20/234 |
| PEG | 0.67x | KR#715/2,436 Sec#45/234 |
| P/S | 0.18x | KR#317/2,436 Sec#2/234 |
| EV/EBITDA | 14.66x | KR#855/2,436 Sec#49/234 |
| FCF Yield | 18.60% | KR#371/2,436 Sec#7/234 |
| Profitability | ||
| ROE | 3.11% | KR#1,217/2,436 Sec#86/234 |
| ROA | 1.68% | KR#1,192/2,436 Sec#90/234 |
| Op. Margin | 2.08% | KR#1,350/2,436 Sec#97/234 |
| Revenue Growth | 8.81% | KR#970/2,436 Sec#87/234 |
| Earnings Growth | 20.67% | KR#746/2,436 Sec#46/234 |
| Financial Health | ||
| Debt Ratio | 185.09% | KR#1,580/2,436 Sec#181/234 |
| Total Debt | 306.19B KRW | KR#390/2,436 Sec#20/234 |
| FCF | 57.15B KRW | KR#272/2,436 Sec#15/234 |
| Cash | 96.62B KRW | KR#476/2,436 Sec#24/234 |
| Current Ratio | 1.30x | KR#1,468/2,436 Sec#157/234 |
| Net Debt/EBITDA | 5.94x | KR#1,140/2,436 Sec#87/234 |
| Dividend | ||
| Div. Yield | 1.65% | KR#993/2,436 Sec#54/234 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | 1.48% | KR#646/2,436 Sec#43/234 |
| 1M Return | 2.49% | KR#337/2,436 Sec#25/234 |
| From 52W High | -51.80% | KR#1,215/2,436 Sec#100/234 |
| 1Y MDD | -52.44% | KR#1,031/2,436 Sec#85/234 |
| Trading | ||
| Volume | 170,493 shares | KR#738/2,436 Sec#65/234 |
| Foreign Own. | 16.65% | KR#279/2,436 Sec#14/234 |
| Per Share | ||
| EPS | 417 KRW | KR#977/2,436 Sec#69/234 |
| BPS | 13,020 KRW | KR#761/2,436 Sec#52/234 |
Company Info
Kwangdong Pharmaceutical, established in 1963 and headquartered in Gwacheon-si, Gyeonggi-do, secured domestic consignment sales rights for Samdasoo until 2029 through a re-contract with Jeju Development Corporation in 2025. The company operates a Pharmacy Business Division for traditional medicines like Ssanghwatang and Woohwangchungsimwon, and an ETC Business Division for specialized pharmaceuticals such as the anti-cancer drug Lenara and vascular fortifier Venitol. Its F&B Sales Division markets beverages like Vita500, Corn Silk Tea, Hogaengnamu Tea, and Jeju Samdasoo, solidifying its brand power in the pharmaceutical and food sectors.